Evidence map›Paper›PMID 29891526›Full record

GuidelineJournal of the National Comprehensive Cancer Network : JNCCN2018

Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Christopher K Bichakjian, Thomas Olencki, Sumaira Z Aasi, Murad Alam, James S Andersen, Rachel Blitzblau, Glen M Bowen, Carlo M Contreras, Gregory A Daniels, Roy Decker and 21 more

Open access · bronzeAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal of the National Comprehensive Cancer Network : JNCCN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 147 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
147citing papers in PubMed, 1 pooled it
16.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

147 citing papers in PubMed, 1 synthesis or guideline pooled it, 314 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. [Merkel cell carcinoma: current surgical approaches and multidisciplinary treatment].Revista medica del Instituto Mexicano del Seguro Social · 2026
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

87 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 20 institutions in 1 country.

Christopher K Bichakjian
Thomas Olencki
Sumaira Z Aasi
Murad Alam
James S Andersen
Rachel Blitzblau
Glen M Bowen
Carlo M Contreras
Gregory A Daniels
Roy Decker
Jeffrey M Farma
Kris Fisher
Brian Gastman
Karthik Ghosh
Roy C Grekin
Kenneth Grossman
Alan L Ho
Karl D Lewis
Manisha Loss
Daniel D Lydiatt
Jane Messina
Kishwer S Nehal
Paul Nghiem
Igor Puzanov
Chrysalyne D Schmults
Ashok R Shaha
Valencia Thomas
Yaohui G Xu
John A Zic
Karin G Hoffmann
Anita M Engh
Memorial Sloan Kettering Cancer Center · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USUniversity of Utah · USCase Western Reserve University · USCity Of Hope National Medical Center · USDana-Farber Brigham Cancer Center · USDuke Medical Center · USFox Chase Cancer Center · USJohns Hopkins University · USMayo Clinic in Arizona · USRoswell Park Comprehensive Cancer Center · USSeattle Cancer Care Alliance · USStanford University · USSusan Thompson Buffett Foundation · USThe Ohio State University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · USUniversity of South Florida · USUniversity of Tennessee Health Science Center · US

Funding

Viral oncoprotein targeted immune therapy for Merkel cell carcinomaR01CA176841 · NCI · UNIVERSITY OF WASHINGTON · PI NGHIEM, PAUL · 2013 to 2016
$2.6M
NCI NIH HHS R01 CA176841
6 · The paper itself

Abstract

This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiation and systemic therapy. Included in these sections are discussion of the new recommendations for use of Merkel cell polyomavirus as a biomarker and new recommendations for use of checkpoint immunotherapies to treat metastatic or unresectable disease. The next update of the complete version of the NCCN Guidelines for MCC will include more detailed information about elements of pathology and addresses additional aspects of management of MCC, including surgical management of the primary tumor and draining nodal basin, radiation therapy as primary treatment, and management of recurrence.

Indexed as

AftercareCarcinoma, Merkel CellChemoradiotherapyHumansIncidenceMedical OncologyMerkel cell polyomavirusSkin NeoplasmsSocieties, MedicalUnited States

Identifiers

PMID29891526
PMCPMC9440150
OpenAlexW2808507967

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.